{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-047085","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.656902+00:00","generated_at":"2026-05-29T20:22:06.216547+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GT Biopharma enters Phase 1 clinical trial agreement with U of Minnesota for GTB-3650 in MDS/AML","bullets":["Agreement for investigator-initiated Phase 1 trial of GTB-3650 (CD16/IL-15/CD33 TriKE) in high-risk MDS, relapsed/refractory AML, MRD.","Budget up to ~$2 million over three years, funded entirely by GT Biopharma.","University of Minnesota sponsors the IND and acts as sponsor-investigator; Company supplies study drug and funding.","Study data owned by University; Company may use data subject to consent and laws; each party may publish results.","Agreement terminable on 30 days' notice by either party, or immediately for safety reasons."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-047085","json":"https://secwatch.observer/filing/0001493152-24-047085.json","markdown":"https://secwatch.observer/filing/0001493152-24-047085.md","text":"https://secwatch.observer/filing/0001493152-24-047085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315224047085/0001493152-24-047085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315224047085/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:22:06.216547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}